tbuckley/cabot-search huggingface dataset:
THE RESISTANCE OF ANTIBODY TO TRYPTIC DIGESTION
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients
Authors: Veena Shankaran, Joseph M Unger, Amy K Darke, Jennifer Marie Suga, James L Wade, Peter J Kourlas, Sreenivasa R Chandana, Mark A O’Rourke, Suma Satti, Diane Liggett, Dawn L Hershman, Scott D Ramsey
Journal: JNCI Journal of the National Cancer Institute (2021)

Abstract Background Financial toxicity is a growing problem in oncology, but no prior studies have prospectively measured the financial impact of cancer treatment in a diverse national cohort of newly diagnosed cancer patients. S1417CD was the first cooperative group-led multicenter prospective cohort study to evaluate financial hardship in metastatic colorectal cancer (mCRC) patients. Methods Patients aged 18 years or older within 120 days of mCRC diagnosis completed quarterly questionnaires for 12 months. We estimated the cumulative incidence of major financial hardship (MFH), defined as 1 or more of increased debt, new loans from family and/or friends, selling or refinancing home, or 20% or more income decline. We evaluated the association between patient characteristics and MFH using multivariate cox regression and the association between MFH and quality of life using linear regression. Results A total of 380 patients (median age = 59.9 years) were enrolled; 77.7% were White, 98.0% insured, and 56.5% had annual income of $50 000 or less. Cumulative incidence of MFH at 12 months was 71.3% (95% confidence interval = 65.7% to 76.1%). Age, race, marital status, and income (split at $50 000 per year) were not statistically significantly associated with MFH. However, income less than $100 000 and total assets less than $100 000 were both associated with greater MFH. MFH at 3 months was associated with decreased social functioning and quality of life at 6 months. Conclusions Nearly 3 out of 4 mCRC patients experienced MFH despite access to health insurance. These findings underscore the need for clinic and policy solutions that protect cancer patients from financial harm.
Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis
Authors: Marc Corbera-Bellalta, Roser Alba-Rovira, Sujatha Muralidharan, Georgina Espígol-Frigolé, Roberto Ríos-Garcés, Javier Marco-Hernández, Amanda Denuc, Farah Kamberovic, Patricia Pérez-Galán, Alexandra Joseph, Annalisa D’Andrea, Kent Bondensgaard, Maria C Cid, John F Paolini
Journal: Annals of the Rheumatic Diseases (2022)

Effective and safe therapies are needed for the treatment of patients with giant cell arteritis (GCA). Emerging as a key cytokine in inflammation, granulocyte-macrophage colony stimulating factor (GM-CSF) may play a role in promoting inflammation in GCA.
Ginger nanoparticles mediated induction of Foxa2 prevents high-fat diet-induced insulin resistance
Authors: Anil Kumar, Kumaran Sundaram, Yun Teng, Jingyao Mu, Mukesh K Sriwastva, Lifeng Zhang, Joshua L. Hood, Jun Yan, Xiang Zhang, Juw Won Park, Michael L Merchant, Huang-Ge Zhang
Journal: Theranostics (2022)

Rationale:The obesity epidemic has expanded globally, due in large part to the increased consumption of high-fat diets (HFD), and has increased the risk of major chronic diseases, including type 2 diabetes.Diet manipulation is the foundation of prevention and treatment of obesity and diabetes.The molecular mechanisms that mediate the diet-based prevention of insulin resistance, however, remain to be identified.Here, we report that treatment with orally administered ginger-derived nanoparticles (GDNP) prevents insulin resistance by restoring homeostasis in gut epithelial Foxa2 mediated signaling in mice fed a high-fat diet (HFD).Methods: Ginger-derived nanoparticles (GDNP) were added into drinking water to treat high-fat diet fed mice for at least one year or throughout their life span.A micro array profile of intestinal, liver and fat tissue of GDNP treated mice was used to analyze their gene expression profile.Genes associated with metabolism or insulin signaling were further quantified using the real time polymerase chain reaction (RT-PCR).Surface plasmon resonance (SPR) was used for determining the interaction between Foxa2 protein and phosphatic acid lipid nanoparticles.Results: HFD-feeding inhibited the expression of Foxa2; the GDNPs increased the expression of Foxa2 and protected Foxa2 against Akt-1 mediated phosphorylation and subsequent inactivation of Foxa2.Increasing expression of Foxa2 leads to altering the composition of intestinal epithelial cell (IEC) exosomes of mice fed a HFD and prevents IEC exosome mediated insulin resistance.Collectively, oral administration of GDNP prevents insulin resistance in HFD mice.Interestingly, oral administration of GDNP also extended the life span of the mice and inhibited skin inflammation.Conclusion: Our findings showed that GDNP treatment can prevent HFD-induced obesity and insulin resistance via protecting the Foxa2 from Akt-1 mediated phosphorylation.GDNP treatment provides an alternative approach based on diet manipulation for the development of therapeutic interventions for obesity.
The wise use of drugs
Authors: W. Modell
Journal: JAMA (1966)

Talks on the art and the science of therapeutics usually begin with the truism that since all drugs are dangerous, their judicious use depends on how the risk of the untreated disease and the risks of the drug are balanced. But no one explains precisely how this concept is to be implemented, and to what extent it actually can be carried out to make the use of a drug a calculated risk. What need to be known in order to use a drug well are the risks of untreated disease and the predictability of the risks of the drug itself. The jeopardy of disease is generally well-established and a critical judgment is usually quite sound, and will, therefore, not be discussed here. <h3>Predictable Reactions</h3> The dangers of drugs are quite another kettle of fish, and they form the practical basis of this paper. Unfortunately, all drug reactions are not calculable
Year Book of Pulmonary Disease
Journal: Thorax (1993)

Allergic alveolitis due to goose feathers in a duvetIt is not often that reports of rare conditions appear in textbooks before journals (November 1992;47:990-1).Allergic alve- olitis due to feathers in cushions, however, was first described in 1975 in a patient in whom I had made the diagnosis some years before.'Although I have not seen a similar patient since, I thought it worthwhile writ- ing in Crofton and Douglas's 4th edition: "One potential source of antigen that may be overlooked is feathers in cushions or pillows".2Incidentally, the patient I looked after had been ill, and a puzzle to her doctors, for about eight years.She had pre- cipitating antibodies to bird serum but no exposure to birds and it was only on my second visit to her house that I tumbled to the possible cause, subsequently confirmed by challenge with the cushion feathers.She was cured by getting rid of the cushions.
Fly Larvæ in the Ear.
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Randomized trial of propafenone, ibutilide, or rate control in post operative atrial fibrillation Richard J. Soucier, Jr., Neal Lippman, Michael L. Therrien, David I. Silverman, Melecio Abordo, Kp Madhusoodanan, Honora Dalamagas, Pritt Jaagosild, Ellison Berns. St Francis Hospital and Medical Center, Hartford, CT, CT
Journal: Journal of the American College of Cardiology (2001)
TRENDS IN PERMANENT PACEMAKER IMPLANTATION IN THE UNITED STATES 1993-2009: INCREASING COMPLEXITY OF PATIENTS AND PROCEDURES
Authors: Arnold J. Greenspon, Jasmine Patel, Edmund Lau, Daniel Frisch, Reginald Ho, Behzad Pavri, Jorge Ochoa, Steven Kurtz
Journal: Journal of the American College of Cardiology (2012)
Alcohol Consumption and Binge Drinking During Pregnancy Among Adults Aged 18–49 Years — United States, 2018–2020
Authors: Lucas K. Gosdin, Nicholas P. Deputy, Shin Y. Kim, Elizabeth P. Dang, Clark H. Denny
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

There is no known safe amount of alcohol consumption during pregnancy; drinking alcohol during pregnancy can cause fetal alcohol spectrum disorders and might increase the risk for miscarriage and stillbirth (1). The prevalence of drinking among pregnant women increased slightly during 2011-2018; however, more recent estimates are not yet reported (2). CDC estimated the prevalence of self-reported current drinking (at least one alcoholic drink in the past 30 days) and binge drinking (consuming four or more drinks on at least one occasion in the past 30 days) among pregnant adults aged 18-49 years, overall and by selected characteristics, using 2018-2020 Behavioral Risk Factor Surveillance System (BRFSS) data. During 2018-2020, 13.5% of pregnant adults reported current drinking and 5.2% reported binge drinking: both measures were 2 percentage points higher than during 2015-2017. Pregnant adults with frequent mental distress were 2.3 and 3.4 times as likely to report current and binge drinking, respectively, compared with those without frequent mental distress. In addition, pregnant adults without a usual health care provider were 1.7 times as likely to report current drinking as were those with a current provider. Alcohol consumption during pregnancy continues to be a serious problem. Integration of mental health services into clinical care and improving access to care might help address alcohol consumption and mental distress during pregnancy to prevent associated adverse outcomes (3).
Myocardial perfusion flow is a prognostic marker in patients with acute myocardial infarction who undergo angioplasty Marcelo O. Bettinotti, Esteban Escolar, Carlos Deluca, Alvaro Sosa Liprandi, Carlos Sztejfman. Sanatorio Mitre, Buenos Aires, Argentina
Journal: Journal of the American College of Cardiology (2001)
Colorectal cancer biomarker, AABH (Aspartyl [Asparaginyl] β- hydroxylase), a companion imaging and treatment strategy.
Authors: Mahmood Moshiri, Kiarash Moshiri, Reza Nazari, Mohammad Pishrochi, Arsha Moshiri, Hassan Monhemi
Journal: Journal of Clinical Oncology (2022)

25 Background: Colorectal cancer (CRC) is the third most common type of cancer diagnosed in the US and Canada. WHO, Canadian Cancer Society (CCS), the National Comprehensive Cancer Network (NCCN) and American Cancer Society (ACS) recommend that men and women begin CRC screening at age 50 or younger if at high risk. Recommended screening procedures: Annual occult fecal blood test (OFBT), a colonoscopy every 5 years, OFBT and colonoscopy every 5 years, or a colonoscopy every 10 years. According to The Surveillance, Epidemiology, and End Results (SEER) Program, only 39% of CRC are diagnosed in stage I, 36% are diagnosed in stage II, 19% are diagnosed with metastasis. The corresponding 5-year survival rates are 89.8%, 67.7%, and 10.3%. Neither the CCS nor the ACS recommends a blood test to be done as part of screening. This is due to the fact that, until now, there has not been a blood test with adequate sensitivity or specificity for screening. Methods: In this study we discovered that aspartyl (asparaginyl) β-Hydroxylase (AABH) measurement in serum can be used as a screening test for CRC. AABH has been detected by immunohistochemical staining (IHC) on the cell surface of different cancers including CRC. It has been detected by IHC in &gt; 97% of tumor specimens tested (n &gt; 210) but has not been found in tissue samples from normal individuals. Results: This observation and the observation that AABH is found in the serum of patients with cancer, but not in non cancer patients, led us to develop a Sandwich ELISA Assay to measure AABH in serum. In the current study we have quantified AABH levels in CRC patients and compared it with normal individual. Increased levels of AABH were found in the serum of 99% of patients with CRC in all different stages of Cancer (n = 277). In normal individuals, AABH was essentially undetectable in serum (n = 195). AABH was identified in serum from patients with CRC irrespective of cancer stage. All serum AABH levels for stages I, II, III and IV were more than 3.0 ng/mL. Conclusions: Thus, our data indicate that by measuring AABH in the serum, we should be able to detect CC at an earlier stage than it is currently detected, resulting to a much better 5-year survival for colon cancer.
Pivotal phase III COMPOSE trial will compare <sup>177</sup>Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors.
Authors: Thorvardur Ragnar Halfdanarson, Diane Lauren Reidy, Namrata Vijayvergia, Daniel M. Halperin, Grace Goldstein, Grace Kong, Michael Michael, Simone Leyden, Simona Grozinsky-Glasberg, Halfdan Sorbye, Kjell E. Oberg, Cristina Sierras, Philip Harris
Journal: Journal of Clinical Oncology (2022)

TPS514 Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which represent approximately 70% of NETs, frequently develop metastatic disease with limited treatment options. Current standard therapies for well-differentiated high grade 2 and grade 3 GEP-NETs include cytoreductive procedures, somatostatin analogues, molecular targeted therapies (everolimus or sunitinib), chemotherapy and peptide receptor radionuclide therapy (PRRT), with no specified sequence of use. PRRT may stabilize disease and induce objective tumor responses. This treatment uses radiolabeled somatostatin analogues to selectively target somatostatin receptor expressing (SSTR+) tumor cells. 177 Lu-edotreotide is an innovative radiolabeled somatostatin analogue with a favorable safety profile and promising efficacy. Retrospective data in metastatic GEP-NETs treated with two or more 177 Lu-edotreotide cycles demonstrated a progression free survival (PFS) of at least 30 months. The currently recruiting Phase III COMPETE trial compares the efficacy and safety of 177 Lu-edotreotide, versus everolimus, in grade 1 and grade 2 GEP-NETs. Methods: COMPOSE (NCT04919226) is a prospective, randomized, controlled, open-label, multi-center Phase III study, in patients with well-differentiated high grade 2 and grade 3 (Ki-67 index 15−55%), SSTR+, GEP-NETs. This trial is to evaluate the efficacy, safety and patient-reported outcomes of first- or second-line treatment with 177 Lu-edotreotide PRRT compared to best standard of care. It aims to randomize 202 patients 1:1 to a defined number of cycles of 177 Lu-edotreotide or an active comparator (either chemotherapy [CAPTEM or FOLFOX] or everolimus, according to investigator´s choice). The primary endpoint is PFS, assessed every 12 weeks until disease progression (RECIST v1.1), or death, whichever occurs earlier. Secondary outcomes include overall survival, assessed up to 2 years after disease progression. Study recruitment for COMPOSE commenced in September 2021. It is expected that COMPOSE will inform optimal treatment options for patients with well-differentiated high grade 2 and grade 3 SSTR+ GEP-NETs, including for first-line therapy. Clinical trial information: NCT04919226.
Regional myocardial flow-metabolism relationship in patients with idiopathic dilated cardiomyopathy Danilo Neglia, Cecilia Marini, Elena Toschi, Oreste Sorace, Piero Salvadori, Gianmario Sambuceti, Oberdan Parodi, Antonio L'Abbate. CNR Institute of Clinical Physiology, Pisa, Italy
Journal: Journal of the American College of Cardiology (2001)
Final angiographic and intravascular ultrasound follow-up results of elimination of restenosis by stenting after plaque reduction with platelet inhibitor trial (ESPRIT) Etsuo Tsuchikane, Tomoko Kobayashi, Nobuhisa Awata, Satoru Otsuji, Makoto Sakurai, Tohru Kobayashi. Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
Journal: Journal of the American College of Cardiology (2001)
Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema
Authors: Michael A. Singer, Veeral Sheth, Sam E. Mansour, Brandon Coughlin, Victor H. Gonzalez
Journal: Ophthalmology (2022)

To assess the long-term safety and efficacy of the 0.19-mg fluocinolone acetonide (FAc) intravitreal implant (Iluvien; Alimera Sciences, Inc) in patients with diabetic macular edema (DME).Three-year, phase 4, nonrandomized, open-label observational study.Patients with DME who previously received corticosteroid treatment without a clinically significant rise in intraocular pressure (IOP; all eyes, n = 202 eyes of 159 patients; 36-month completion, n = 94 eyes).A prospective, observational study in which patients received a 0.19-mg FAc intravitreal implant at baseline and then were observed for safety-, visual-, anatomic-, and treatment burden-related outcomes for up to 36 months.Primary safety outcomes included changes in IOP and interventions to manage IOP elevations. Secondary outcomes included changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), and adjunctive DME treatment frequency RESULTS: At 36 months after FAc implantation, study eyes showed a mean CST change of -60.69 μm (P < 0.0001) and a mean BCVA change of +3.61 letters (P = 0.0222) compared with baseline. Overall median treatment frequency decreased from 3.4 treatments/year in the 36 months before FAc implantation to 1 treatment/year in the 36 months after FAc implant, a treatment burden reduction of 70.5%. Furthermore, among the group that completed 36 months of treatment (n = 94 eyes), 25.53% of eyes remained rescue free through 36 months. Mean IOP remained stable throughout the study, and IOP increases to more than 30 mmHg occurred in 10.89% of eyes. Intraocular pressure-related procedures were infrequent, with a surgical rate of 2.97%, with 1.49% attributable to steroid use (vs. surgeries attributable primarily to neovascular glaucoma). In addition, an IOP response of < 25 mmHg after the steroid challenge predicted that 96.92% of eyes would have a similar outcome to 0.19-mg FAc implant at the last visit. Intraocular pressure increases that did occur were manageable with standard treatments (n = 202 eyes).In patients with DME, the 0.19-mg FAc implant provided improved visual outcomes and reduced treatment burden compared with previous treatments while maintaining a favorable safety profile.
mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS mutant unresectable colorectal liver-limited metastases: A study protocol of a multicenter randomized controlled phase 3 (BECOME2) trial.
Authors: Wentao Tang, Ye Wei, Li Ren, Qing-Hai Ye, Tianshu Liu, Jianmin Xu
Journal: Journal of Clinical Oncology (2022)

TPS228 Background: Colorectal cancer patients with initially unresectable liver-only metastases may be cured after downsizing of metastases by conversion therapy. However, the optimal regimen of conversion therapy for RAS mutant patients has not been defined. Methods: BECOME2 is a multicenter, randomized, phase 3 clinical study. RAS mutant and BRAF wild type colorectal cancer patients with initially unresectable liver-limited metastases are eligible. The (un)resectability status is prospectively assessed by a central multidisciplinary team (MDT) consisting of at least one radiologist and three liver surgeons, according to predefined criteria. RAS and BRAF mutation status were evaluated according to primary tumor. Patients with RAS mutant and BRAF wild type will be randomized between modified FOLFOXIRI (IRI, 165mg/m2; Oxa, 85mg/m2; LV, 400mg/m2; 5-FU 2400mg/m2) plus bevacizumab (5mg/kg) and modified FOLFOX6 (mFOLFOX6) plus bevacizumab. Radiological evaluation to assess conversion to resectability will be performed by the central MDT every eight weeks. The primary study endpoint is conversion resection rate. Secondary endpoints are the ETS, DpR, ORR, PFS, OS, toxicity, perioperative complication, and the proportion of no evidence of disease. Clinical trial information: NCT04781270.
Endoscopy International Open – recently published
Journal: Endoscopy (2021)

Comment on:Implementation and results of a gastrointestinal cancer screening program in an Amazon rainforest village: A descriptive studyEndosc Int Open 2021; 09(06): E770-E776DOI: 10.1055/a-1386-2095Comment on:Scoring systems in clinical small-bowel capsule endoscopy: all you need to know!Endosc Int Open 2021; 09(06): E802-E823DOI: 10.1055/a-1372-4051Comment on:Do endosonographers agree on the presence of bile duct sludge and the subsequent need for intervention?Endosc Int Open 2021; 09(06): E911-E917DOI: 10.1055/a-1452-8919
A Correction
Journal: BMJ (1919)

Ehgagemeute (that is, Form T 124 and its variants), in the Army, or in the Royal Air Force, have in many cases per- formed service during some other part of the War which would entitle them to the Mercantile Marine War Medal.Such officers, men and women, will be awarded the Mer- eantile Marine War Medal if their olaims are approved, apart from any further medal which they may be awarded under the regulations of the
Efficacy of<i>Helicobacter pylori</i>eradication therapy for functional dyspepsia: updated systematic review and meta-analysis
Authors: Alexander C Ford, Evangelos Tsipotis, Yuhong Yuan, Grigorios I Leontiadis, Paul Moayyedi
Journal: Gut (2022)

Functional dyspepsia (FD) is a chronic disorder that is difficult to treat.